SABCS 2023 | POETIC trial: genomic characterization of endocrine resistance in ER+HER2+ BC

Maggie Chon U Cheang, MD, PhD, Institute of Cancer Research, London, UK, talks on the Phase III POETIC trial (NCT02338310) of post-menopausal patients with ER+HER2+ invasive breast cancer. Patients were randomized to receive per-operative aromatase inhibitors versus control, followed by standard of care treatment. Dr Cheang highlights findings related to TP53 mutations, revealing that in the HER2-enriched subtype, these mutations are associated with a good response. However, in cases excluding Her2-enriched with positive HER2-negative tumors, TP53 mutations are linked to a poor response. Integration of spatial whole transcriptomic and proteomic data unveils increased heterogeneity and identifies potential therapeutic targets, providing valuable insights for ER+HER2+ breast cancer management. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.